Time period | Total | SARS-CoV-2 + | SARS-CoV-2- | Not tested | ||||
---|---|---|---|---|---|---|---|---|
Adjusted % positive GN/GP culture | % Prescribed Abx therapy ≥ 24 h | Adjusted % positive GN/GP culture | % Prescribed Abx therapy ≥ 24 h | Adjusted % positive GN/GP culture | % Prescribed Abx therapy ≥ 24 h | Adjusted % positive GN/GP culture | % Prescribed Abx therapy ≥ 24 h | |
Pre-pandemic: July 2019–Feb 2020 | 9.49 (8.86–10.13) | 36.66 (35.46–37.87) | NA | NA | NA | NA | NA | NA |
March 2020–May 2020 | 9.61 (8.98–10.24) | 37.76 (36.97–38.55) | 13.34 (12.45–14.23) | 68.02 (66.57–69.46) | 12.23 (11.32–13.13) | 46.99 (45.49–48.49) | 8.51 (7.88–9.13) | 32.48 (31.15–22.81) |
June 2020–August 2020 | 9.38 (8.75–10.01) | 35.50 (34.31–36.69) | 12.89 (11.77–14.00) | 62.82 (60.55–65.08) | 11.08 (10.17–11.99) | 40.30 (38.87–41.73) | 6.81 (6.17–7.44) | 29.44 (28.11–20.78) |
Sept 2020–Nov 2020 | 9.57 (8.95–10.20) | 36.89 (35.70–38.08) | 11.60 (10.52–12.69) | 57.49 (54.27–58.72) | 10.99 (10.03–11.94) | 40.00 (38.56–41.44) | 6.92 (6.29–7.55) | 30.90 (29.57–32.24) |
Dec 2020–Feb 2021 | 9.69 (9.06–10.33) | 38.43 (37.24–39.62) | 11.69 (10.75–12.63) | 57.31 (55.11–59.51) | 10.88 (9.95–11.80) | 39.57 (38.12–41.01) | 6.71 (6.08–7.34) | 31.67 (30.33–33.01) |
March 2021–May 2021 | 9.17 (8.53–9.81) | 36.01 (34.81–37.21) | 11.72 (10.76–12.68) | 54.10 (51.84–56.36) | 10.38 (9.47–11.30) | 39.48 (38.02–40.95) | 6.50 (5.87–7.14) | 30.13 (28.78–31.48) |
June 2021–October 2021 | 9.35 (8.76–9.94) | 36.18 (35.05–37.32) | 10.99 (9.73–12.25) | 53.59 (51.50–55.67) | 10.93 (10.07–11.80) | 39.38 (38.01–40.74) | 6.61 (6.02–7.20) | 31.01 (29.73–32.29) |